Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white

“Darnitsa” is the main supplier of medicines for the population – Shymkiv

17 November 2021

Pharmaceutical company “Darnitsa” holds leading positions on Ukrainian market of pharmaceutical products*. This was said by Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group, in an interview to Andriy Pavlushynֹ’s YouTube channel “Careerist”.

During the conversation, Dmytro Shymkiv said that “Darnitsa” remains focused on the domestic consumer. 95% of its products are available on the shelves of Ukrainian pharmacies or are purchased centrally by medical institutions.

According to the infographic guidebook “Pharmaceuticals of Ukraine”, every Ukrainian consumed drugs for $96 in 2020 in average, which is $7 more than in 2019. The authors of the guidebook state that this is quite a significant growth rate.

In 2020, compared with 2010, Ukrainian citizens began to buy more over-the-counter drugs and, consequently, less of those that are available by prescription. The most purchased drugs are those for the digestive system and metabolism, cardiovascular and nervous system. In particular, Citramon, which is produced by “Darnitsa”, is among the top 5 most popular drugs in Ukraine by volume of sales in monetary terms.

Steadily high demand encourages the company to increase production volumes, as well as to improve the efficiency of the production process. According to Shimkiv, about a tenth of the company’s profits are spent on upgrading its production infrastructure, digitalization and pharmaceutical research. Today, for example, the 5-storey warehouse of “Darnitsa” is served by four robots.

“1 040 people work at the company “Darnitsa”. We have 177 brands. The company has good growth dynamics – double-digit numbers year after year, – remarked Dmytro Shymkiv. – This year we are launching 21 new drugs on the Ukrainian market.”

On this background, the pharmaceutical company for several years has been occupying the first place by sales volume in kind (14.6% of the market, while the closest competitors have 8%) and holds the second place by its share in monetary terms.

Earlier, Dmytro Shymkiv said that “Darnitsa” as a leader in the pharmaceutical market* is focused on expanding access to treat with effective and safe drugs as many people as possible, while the most vulnerable categories of people are provided with free medicines due to partnerships with non-governmental organizations. 

*in volume, infographic guide “Pharmaceutics of Ukraine 2021”, Top Lead

Share:
Specialized edition for medical institutions and doctors.